Purpose: To determine the intraocular levels of methotrexate in low-dose treatment of noninfectious uveitis. Methods: One day after oral administration, the methotrexate level was measured in the aqueous humor and serum of a patient with noninfectious uveitis, who underwent cataract surgery. A fluorescence polarization immunoassay was used for determination. Results: After oral administration, methotrexate was only measurable in aqueous humor but not in serum. Conclusion: In uveitis, orally administered low-dose methotrexate reaches detectable levels in aqueous humor, even in the absence of detectable levels in serum.

Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, Volcker HE: Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992;1:142–144.
Wong VG, Hersh EM: Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol 1965;69:279–293.
Ravelli I, Martini H: Methotrexate in juvenile idiopathic arthritis: Answers and questions. J Rheumatol 2000;27:1830–1833.
De Smet MD, Stark-Vancs V, Kohler DR, Smith J, Wittes R, Nussenblatt RB: Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 1996;121:442–444.
Henson JW, Yang J, Batchelor TT: Intraocular methotrexate levels after high-dose intravenous infusion. J Clin Oncol 1999;17:1329.
Kurnik D, Loebstein, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y: Bioavailability of oral vs subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther 2003;18:57–63.
Oguey D, Kolliker F, Gerber NJ, Reichen J: Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:611–614.
Hamilton RA, Kremer JM: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86–90.
Chladek J, Grim J, Martinkova J, Simkova M, Vaniekova J, Koudelkova V, Noiekova M: Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002;54:147–156.
Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J: Clinical pharmacokinetics of low dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194–210.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.